EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte StudieKlinische Studie (Phase III)Multizentrische StudieOpen Access · CC BY-NC 4.0

Efficacy and Safety of Guselkumab in Participants With Active Psoriatic Arthritis After Inadequate Response to One Prior Tumor Necrosis Factor Inhibitor: Week‐24 Results of a Phase 3, Randomized, Placebo‐Controlled Study

Alexis Ogdie iD, Joseph F Merola iD, Philip J Mease iD, Christopher T Ritchlin iD, Jose U Scher iD, Kimberly Parnell Lafferty, Daphne Chan, Soumya D Chakravarty iD, Wayne Langholff, Yanli Wang, Jie Shao, Yevgeniy Krol und 1 weitere

Arthritis & Rheumatology · 2026-08 · 78 (8) · 1674-1686

DOI: 10.1002/art.70092 ↗

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift Arthritis & Rheumatology, online erschienen am 16.04.2026. Verfasst von Alexis Ogdie und 12 weiteren Autor:innen. Beteiligte Einrichtung: Perelman School of Medicine, University of Pennsylvania, Philadelphia. Hauptthemen laut MEDLINE: Arthritis, Psoriatic, Antibodies, Monoclonal, Humanized, Antirheumatic Agents. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 43 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Johnson & Johnson, Johnson and Johnson.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Objective

To evaluate the efficacy and safety of guselkumab, an interleukin‐23p19 subunit inhibitor, in participants with active psoriatic arthritis (PsA) and inadequate response (inadequate efficacy and/or intolerance) to one prior tumor necrosis factor (TNF) inhibitor.

Methods

In SOLSTICE (phase 3b, randomized, multicenter, double‐blind, placebo‐controlled study), enrolled adults with active PsA (three or more swollen joints; three or more tender joints; C‐reactive protein ≥ 0.3 mg/dL) and inadequate response to one prior TNF inhibitor were randomized to guselkumab 100 mg every 4 weeks (Q4W), guselkumab 100 mg at weeks 0 and 4 and then Q8W, or placebo with crossover to guselkumab Q4W at week 24. The primary endpoint was ≥20% improvement in American College of Rheumatology criteria (ACR20) at week 24. Secondary endpoints included ACR50, ACR70, Investigator's Global Assessment of psoriasis (IGA) score of 0 or 1 with ≥2‐grade improvement, ≥90% improvement in Psoriasis Area and Severity Index (PASI90), and minimal disease activity (MDA) at week 24 and were analyzed by intention‐to‐treat.

Results

Analyses included 451 randomized participants (Q4W n = 150; Q8W n = 151; placebo n = 150). At week 24, significantly greater proportions of guselkumab (Q4W/Q8W)‐treated participants versus placebo‐treated participants, respectively, achieved ACR20 (primary endpoint: 58.6%/62.2% vs 34.8%), ACR50 (31.4%/32.1% vs 12.2%), ACR70 (17.5%/17.3% vs 2.0%), IGA 0/1 response (50.0%/57.3% vs 17.4%), PASI90 (49.4%/45.5% vs 12.0%), and MDA (18.8%/23.9% vs 5.4%) (all P < 0.001). Through week 24, 46.7%, 53.6%, and 48.3% of participants receiving guselkumab Q4W, guselkumab Q8W, and placebo, respectively, had one or more adverse event. One death occurred (myocardial infarction).

Conclusion

Comparable efficacy was observed with both guselkumab regimens in participants with active PsA and inadequate response to one prior TNF inhibitor; safety findings were consistent with the known profile of guselkumab in patients with psoriatic disease. image

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Arthritis, PsoriaticAntibodies, Monoclonal, HumanizedAntirheumatic AgentsHumansMaleFemaleDouble-Blind MethodMiddle AgedAdultTreatment OutcomeCross-Over StudiesTumor Necrosis Factor-alphaTumor Necrosis Factor InhibitorsSeverity of Illness Index

Substanzen

Antibodies, Monoclonal, HumanizedguselkumabAntirheumatic AgentsTumor Necrosis Factor-alphaTumor Necrosis Factor Inhibitors

Autor:innen und Institutionen

  • Perelman School of Medicine, University of Pennsylvania, Philadelphia.
  • University of Texas Southwestern Medical Center, Dallas, Texas.
  • University of Texas Southwestern O'Donnell School of Public Health, Dallas.
  • Rheumatology Research, Providence Swedish Medical Center, Seattle, Washington.
  • University of Washington School of Medicine, Seattle, Washington.
  • University of Rochester Medical Center, Rochester, New York.

ORCID-Profile: Alexis Ogdie, Joseph F Merola, Philip J Mease, Christopher T Ritchlin, Jose U Scher, Soumya D Chakravarty, Alice B Gottlieb

Förderung

  • Johnson & Johnson
  • Johnson and Johnson

Zitieren

APA

Ogdie, A., Merola, J. F., Mease, P. J., Ritchlin, C. T., Scher, J. U., Lafferty, K. P., Chan, D., Chakravarty, S. D., Langholff, W., Wang, Y., Shao, J., Krol, Y., & Gottlieb, A. B. (2026). Efficacy and Safety of Guselkumab in Participants With Active Psoriatic Arthritis After Inadequate Response to One Prior Tumor Necrosis Factor Inhibitor: Week‐24 Results of a Phase 3, Randomized, Placebo‐Controlled Study. Arthritis & Rheumatology, 78(8), 1674-1686. https://doi.org/10.1002/art.70092

Vancouver

Ogdie A, Merola JF, Mease PJ, Ritchlin CT, Scher JU, Lafferty KP, et al. Efficacy and Safety of Guselkumab in Participants With Active Psoriatic Arthritis After Inadequate Response to One Prior Tumor Necrosis Factor Inhibitor: Week‐24 Results of a Phase 3, Randomized, Placebo‐Controlled Study. Arthritis & Rheumatology. 2026;78(8):1674-1686. doi:10.1002/art.70092

BibTeX
@article{Ogdie2026,
  author = {Ogdie, Alexis and Merola, Joseph F and Mease, Philip J and Ritchlin, Christopher T and Scher, Jose U and Lafferty, Kimberly Parnell and Chan, Daphne and Chakravarty, Soumya D and Langholff, Wayne and Wang, Yanli and Shao, Jie and Krol, Yevgeniy and Gottlieb, Alice B},
  title = {Efficacy and Safety of Guselkumab in Participants With Active Psoriatic Arthritis After Inadequate Response to One Prior Tumor Necrosis Factor Inhibitor: Week‐24 Results of a Phase 3, Randomized, Placebo‐Controlled Study},
  journal = {Arthritis & Rheumatology},
  year = {2026},
  volume = {78},
  number = {8},
  pages = {1674--1686},
  doi = {10.1002/art.70092}
}
Kostenlos starten →